In MM patients, blood plasma profiling for markers beyond monoclonal M-protein and free light chain ratio include, among others, VEGF, transforming growth factor (TGF), epidermal growth factor (EGF)-2, and monocyte chemotactic protein-3, which in principle aim at patient stratification into distinct prognostic groups. Here, VEGFA is linked to Miyoshi myopathy.